Obesity is an aggravating factor in relapsing-remitting multiple sclerosis, the most common form of the disease. A recent study by the Unit of Neurology and Neuro rehabilitation of the I.R.C.C.S. Neuromed in Pozzilli (Italy) confirms that lipid metabolism can have a role in determining the severity of multiple sclerosis. Published in the Multiple Sclerosis Journal, the research, involving...
Tag: <span>Multiple sclerosis</span>
Post
Deletion in mouse neutrophils offers clues to pathogenesis in multiple sclerosis
by Jeff Hansen, University of Alabama at Birmingham Multiple sclerosis is an autoimmune disease that damages the insulating sheaths of nerve cells of the central nervous system. People with the disease can lose vision, suffer weak limbs, show degenerative symptoms and exhibit impaired cognition. While multiple sclerosis has 17 approved therapies to modify the disease, none is able to halt disease...
Post
AAN: Oral BTK inhibitor superior to placebo in multiple sclerosis
Xavier Montalban, M.D., Ph.D., from the Vall d’Hebron University Hospital in Barcelona, Spain, and colleagues conducted a randomized phase 2 trial involving patients with relapsing multiple sclerosis. A total of 267 patients were randomly assigned to one of five groups: placebo, evobrutinib (at doses of 25 mg once daily, 75 mg once daily, or 75 mg twice daily),...
Post
Study finds that many people diagnosed with MS do not have the condition
By Chiara Townley Fact checked by Paula Field Researchers found that nearly 1 in 5 people who had received a diagnosis of multiple sclerosis had other unrelated conditions. Multiple sclerosis (MS) is a widespread disabling neurological condition in which the immune system attacks and destroys the fatty tissue that surrounds the nerves. This leads to...
Post
FDA approves mavenclad for treating multiple sclerosis
(HealthDay)—Mavenclad (cladribine) tablets were approved to treat adult patients with relapsing-remitting and active secondary progressive multiple sclerosis (MS) who have inadequately responded to or cannot tolerate an alternate drug for MS, the U.S. Food and Drug Administration announced Friday. The approval was based on efficacy data from a clinical trial of 1,326 patients with relapsing forms of MS who...
Post
Do minerals play a role in development of multiple sclerosis?
by American Academy of Neurology Some studies have suggested that minerals such as zinc and iron may play a role in how multiple sclerosis (MS) progresses, once people have been diagnosed with it. But little was known about whether zinc, iron and other minerals play a role in the development of the disease. A new study...
Post
FDA Approves Siponimod (Mayzent ) for Multiple Sclerosis
Susan Jeffrey March 26, 2019 The US Food and Drug Administration (FDA) has approved siponimod(Mayzent, Novartis) to treat adults with relapsing forms of multiple sclerosis(MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive (SP) disease, the agency announced. “Multiple sclerosis can have a profound impact on a person’s life,” Billy Dunn, MD, director of the...
Post
Non-contrast MRI is effective in monitoring multiple sclerosis patients
Brain MRI without contrast agent is just as effective as the contrast-enhanced approach for monitoring disease progression in patients with multiple sclerosis (MS), according to a new study in the journal Radiology. The findings support the possibility that contrast enhancement can be omitted from routine follow-up scans. MS is a disease in which the immune...
Post
Soda, sugar-sweetened beverages linked to more severe symptoms for people with multiple sclerosis
For people with multiple sclerosis (MS), drinking around 290 calories per day of soda or other sugar-sweetened beverages, or the equivalent of about two cans of non-diet soda, may be tied to more severe symptoms and a higher level of disability compared to people with MS who seldom consume sugar-sweetened beverages, according to a preliminary...
Post
Contributors to delay of multiple sclerosis diagnosis ID’d
Laura Barin, from the University of Zurich, and colleagues examined data from the Swiss MS Registry to identify possible causes of delay in the diagnostic process for 522 patients. The time from first contact to the first consultation and evaluation-to-diagnosis time were modeled. The researchers found that general practitioners were mostly contacted first (67 percent), which did not delay diagnosis. First symptoms...